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Backround: Melanoma is malignant disease with increasing incidency. Treatment 
of advanced stage of melanoma is still limited. With a progress of knowledge 
in genetics and tumorigenesis, the incidence of mutated BRAF protein was observed 
at 50 % of melanomas. In 80-90 % mutated melanomas contain BRAF V600E mutation. 
The aim of study was to establish a suitable molecular biological method for the 
diagnosis of mutations in codon V600 BRAF. 
Methods: Cobas 4800 BRAF V600 mutation test and BRAF StripAssay test were used 
to analyze DNA. Cobas 4800 BRAF V600 mutation test is based on PCR using TaqMan 
probes designed for the wild-type and mutant BRAF V600E sequence. BRAF 
StripAssay test is based on PCR amplification with biotinylated primers and subsequent 
hybridization of the stripped with allele-specific oligonucleotide probes. Examined 
DNA samples were derived from 35 patients with advanced malignant melanoma 
or from archive of laboratory. 
Results: BRAF V600 mutation was detected in approximately half of the tumors, 
consistent with the results of other studies. In comparison methods Cobas test went 
better. Part of the samples was by Cobas 4800 BRAF V600 test positive, but by BRAF 
STRIPASSAY was detected as BRAF V600E negative. This suggests that the samples 
could carry V600K and BRAF V600D mutation or insufficient sensitivity BRAF 
STRIPASSAY test. In two metastases were detected mutations, although the primary 
tumor was negative (wild-type). 
Conclusions: The cobas 4800 BRAF V600 showed greater sensitivity and a wider range 
of captured mutation compared with BRAF StripAssay. Different quality or sensitivity 
of the test is diagnostically significant. Results indicate that Cobas 4800 BRAF V600 
test could be used to diagnose almost 100% of mutated BRAF melanomas. The 
detection of mutations correspond literature. The results show the importance of testing 
real-time sample pre-treatment, metastases can not rely on the results of the examination 
of the tumor. 
